OR WAIT null SECS
Quanticate and Cancer Research UK have launched the DETERMINE study which will test a range of therapies specifically targeting key genetic changes in cancer cells.
The DETERMINE study will enroll patients with rare cancers, and aim to find out whether existing licensed drugs could be used to treat their type of cancer. Cohorts will be formed of patients who have an identifiable genetic alteration in their cancer that can be targeted by treatments already approved for use in other cancer types.
Read more about the study here.